(Q37797998)

23 August 2017

title

Targeted oral therapies in the treatment of pulmonary arterial hypertension (English)

1 reference

23 August 2017

main subject

arterial hypertension

0 references

author name string

Zeenat Safdar

series ordinal

1

1 reference

23 August 2017

publication date

1 January 2010

1 reference

Clinical Drug Investigation

23 August 2017

published in

1 reference

23 August 2017

volume

30

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

811-826

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

23 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11538870-000000000-00000

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11538870-000000000-00000

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

12 December 2020

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

1 reference

12 December 2020

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.

1 reference

12 December 2020

Sildenafil citrate therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

1 reference

12 December 2020

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

1 reference

12 December 2020

Inhaled iloprost for severe pulmonary hypertension

1 reference

12 December 2020

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

1 reference

12 December 2020

Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.

1 reference

12 December 2020

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension

1 reference

12 December 2020

Tadalafil therapy for pulmonary arterial hypertension.

1 reference

12 December 2020

Overview of phosphodiesterase 5 inhibition in erectile dysfunction

1 reference

12 December 2020

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

1 reference

12 December 2020

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension

1 reference

12 December 2020

Teratogenic effects of the endothelin receptor antagonist L-753,037 in the rat

1 reference

12 December 2020

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

1 reference

12 December 2020

Phosphodiesterase type 5: expanding roles in cardiovascular regulation

1 reference

12 December 2020

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

1 reference

12 December 2020

Treatment of pulmonary arterial hypertension

1 reference

12 December 2020

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

12 December 2020

The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.

1 reference

12 December 2020

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

1 reference

12 December 2020

Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions

1 reference

12 December 2020

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects

1 reference

12 December 2020

Medical therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Comparison of phosphodiesterase type 5 (PDE5) inhibitors

1 reference

12 December 2020

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

1 reference

12 December 2020

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

1 reference

12 December 2020

Endothelin-1: the yin and yang on vascular function.

1 reference

12 December 2020

The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect

1 reference

12 December 2020

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

1 reference

12 December 2020

Pulmonary arterial hypertension in France: results from a national registry

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Novel phosphodiesterase-5 inhibitors: current indications and future directions.

1 reference

12 December 2020

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

12 December 2020

Tadalafil pharmacokinetics in healthy subjects

1 reference

12 December 2020

Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation.

1 reference

12 December 2020

Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers

1 reference

12 December 2020

Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin

1 reference

12 December 2020

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

1 reference

12 December 2020

Ambrisentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Survival with first-line bosentan in patients with primary pulmonary hypertension.

1 reference

12 December 2020

10.2165/11538870-000000000-00000

Identifiers

DOI

1 reference

23 August 2017

1 reference